Hemgenix (Etranacogene Dezaparvovec)

Hemgenix (etranacogene dezaparvovec) is an intravenously administered gene‑therapy product indicated for the treatment of hemophilia B. It delivers a functional copy of the factor IX gene to liver cells using an adeno‑associated viral vector, enabling the body to produce its own functional factor IX protein and reduce bleeding episodes.

Hemgenix is prescribed for patients with hemophilia B to provide a long‑term therapeutic option. It is used in clinical practice to: - Reduce the frequency of spontaneous bleeding events. - Decrease reliance on regular factor IX replacement infusions. - Improve overall quality of life for individuals with moderate to severe hemophilia B. - Offer a potentially durable solution through a single administration. - Complement existing hemophilia B management strategies when appropriate.

Common side effects of Hemgenix are generally mild and may include: - Transient elevation of liver enzymes. - Low‑grade fever or flu‑like symptoms. - Injection site reactions such as redness or swelling. - Nausea or mild gastrointestinal discomfort.

Serious side effects, although less frequent, require medical attention: - Severe liver inflammation or hepatitis. - Immune reactions to the viral vector. - Thrombotic events or clot formation. - Development of inhibitors against factor IX. - Unexplained bleeding despite therapy.

Before initiating Hemgenix therapy, several precautions should be considered: - Assess baseline liver function and monitor regularly during treatment. - Evaluate for pre‑existing antibodies to adeno‑associated viruses. - Discuss potential risks with patients who have a history of severe allergic reactions. - Use caution in individuals with active infections or immunocompromised status. - Counsel women of childbearing potential about unknown pregnancy safety data. - Ensure appropriate follow‑up for long‑term safety monitoring.

Hemgenix may interact with other medications or therapies as follows: Avoid: - Concurrent use of strong immunosuppressants that could diminish vector efficacy. - Live vaccines administered shortly before or after gene therapy. Use with caution: - Anticoagulants or antiplatelet agents, due to altered bleeding risk. - Other factor IX replacement products, which may affect dosing assessments. - Medications known to affect liver enzymes, requiring closer hepatic monitoring. - Experimental gene‑editing agents, pending further safety data.